STOCK TITAN

Globus Medical (NYSE: GMED) director exercises options, sells 25,000 shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

GLOBUS MEDICAL INC (GMED) director Stephen T. Zarrilli reported an option exercise and same-day stock sale. He exercised 25,000 stock options for Class A Common Stock at an exercise price of $53.27 per share, then sold 25,000 shares of Class A Common Stock at a weighted average price of $87.0386 per share in multiple transactions. The options exercised were fully vested and, after the exercise, the reported option position in this grant was 0 shares.

Positive

  • None.

Negative

  • None.
Insider ZARRILLI STEPHEN T
Role Director
Sold 25,000 shs ($2.18M)
Approx. gross sale proceeds $2.18M
Approx. exercise cost $1.33M
Approx. pre-tax spread $844K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy Class A Common Stock) F2 25,000 $0.00 $0.00
Exercise Class A Common Stock 25,000 $53.27 $1.33M
Sale Class A Common Stock F1 25,000 $87.0386 $2.18M
Holdings After Transaction: Stock Option (Right to Buy Class A Common Stock) — 0 shares (Direct); Class A Common Stock — 0 shares (Direct)
Footnotes (2)
  1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.92 to $87.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
  2. F2. These options were granted on January 22, 2020 and are fully vested.
Options exercised 25,000 shares Stock Option (Right to Buy Class A Common Stock) exercised on 2026-08-18
Option exercise price $53.27 per share Conversion or exercise price for 25,000 underlying shares
Shares sold 25,000 shares Class A Common Stock sale on 2026-08-18
Weighted average sale price $87.0386 per share Weighted average for multiple sale transactions, prices $86.92–$87.16
Sale price range $86.92–$87.16 per share Range of prices for the multiple sale transactions described in footnote (1)
Option grant date January 22, 2020 Date the reported options were granted; they are now fully vested
Option expiration date 2030-01-22 Expiration date for the exercised stock options
Options remaining in this grant 0 shares Total shares following option transaction for this grant
Stock Option (Right to Buy Class A Common Stock) financial
"security_title: Stock Option (Right to Buy Class A Common Stock)"
Class A Common Stock financial
"underlying_security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

What insider transaction did GMED director Stephen T. Zarrilli report on this Form 4?

Stephen T. Zarrilli reported exercising 25,000 stock options for Globus Medical Class A Common Stock and selling 25,000 shares on the same day. The filing shows this as an option exercise followed by an open-market or private sale transaction.

How many Globus Medical (GMED) shares did Stephen T. Zarrilli sell, and at what price?

He sold 25,000 shares of Globus Medical Class A Common Stock at a $87.0386 weighted average price. Footnotes explain these shares were sold in multiple trades, with prices ranging from $86.92 to $87.16 per share, inclusive.

What was the exercise price of the options exercised by GMED director Stephen T. Zarrilli?

The options exercised had an exercise price of $53.27 per share for 25,000 underlying shares of Class A Common Stock. These options were originally granted on January 22, 2020 and were fully vested at the time of the reported transaction.

Did Stephen T. Zarrilli retain any options from this specific Globus Medical grant after the transaction?

For this specific option grant, the reported balance after the transaction is 0 options remaining. The Form 4 lists the total shares following the option transaction as zero, indicating this particular grant was fully exercised according to the filing.

Were the reported Globus Medical (GMED) share sales by Stephen T. Zarrilli under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked as an affirmative trading plan. The footnotes do not describe the transactions as made under a pre-arranged Rule 10b5-1 trading plan, based on the information provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ZARRILLI STEPHEN T

(Last)(First)(Middle)
VALLEY FORGE BUSINESS CENTER
2560 GENERAL ARMISTEAD AVENUE

(Street)
AUDUBON PENNSYLVANIA 19403

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock08/18/2026M25,000A$53.2725,000D
Class A Common Stock08/18/2026S25,000D$87.0386(1)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)$53.2708/18/2026M25,000 (2)01/22/2030Class A Common Stock25,000$00D
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.92 to $87.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
2. These options were granted on January 22, 2020 and are fully vested.
/s/ Kelly G. Huller, Attorney-in-Fact08/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)